BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takahashi H, Arimura Y, Yamashita K, Okahara S, Tanuma T, Kodaira J, Hokari K, Tsukagoshi H, Shinomura Y, Hosokawa M. Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol 2010;5:122-8. [PMID: 19898259 DOI: 10.1097/JTO.0b013e3181c1ffd5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Ohnuma H, Sato Y, Hayasaka N, Matsuno T, Fujita C, Sato M, Osuga T, Hirakawa M, Miyanishi K, Sagawa T, Fujikawa K, Ohi M, Okagawa Y, Tsuji Y, Hirayama M, Ito T, Nobuoka T, Takemasa I, Kobune M, Kato J. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study. Cancer Sci. 2018;109:3554-3563. [PMID: 30137686 DOI: 10.1111/cas.13772] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
2 Hironaka S, Tsubosa Y, Mizusawa J, Kii T, Kato K, Tsushima T, Chin K, Tomori A, Okuno T, Taniki T, Ura T, Matsushita H, Kojima T, Doki Y, Kusaba H, Fujitani K, Taira K, Seki S, Nakamura T, Kitagawa Y; Japan Esophageal Oncology Group/Japan Clinical Oncology Group. Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci 2014;105:1189-95. [PMID: 25041052 DOI: 10.1111/cas.12486] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
3 Sugase T, Makino T, Yamasaki M, Tanaka K, Hashimoto T, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Mano M, Morii E, Mori M, Doki Y. Histological changes of superficial esophageal squamous cell carcinoma after preoperative chemotherapy. Esophagus 2018. [PMID: 29909488 DOI: 10.1007/s10388-018-0626-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Tanaka Y, Yoshida K, Yamada A, Tanahashi T, Okumura N, Matsuhashi N, Yamaguchi K, Miyazaki T. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2016;77:1143-52. [PMID: 26896963 DOI: 10.1007/s00280-016-2985-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
5 Shi Y, Qin R, Wang ZK, Dai GH. Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma. Onco Targets Ther 2013;6:585-91. [PMID: 23737672 DOI: 10.2147/OTT.S44406] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
6 Hosoda K, Yamashita K, Tsuruta H, Moriya H, Mieno H, Ema A, Washio M, Watanabe M. Prognoses of advanced esophago-gastric junction cancer may be modified by thoracotomy and splenectomy. Oncol Lett 2018;15:1200-10. [PMID: 29399174 DOI: 10.3892/ol.2017.7441] [Reference Citation Analysis]
7 Tanaka Y, Yoshida K, Sanada Y, Osada S, Yamaguchi K, Takahashi T. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol. 2010;66:1159-1165. [PMID: 20878160 DOI: 10.1007/s00280-010-1447-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
8 Ojima T, Nakamura M, Nakamori M, Katsuda M, Hayata K, Kitadani J, Maruoka S, Shimokawa T, Yamaue H. Triplet chemotherapy with docetaxel, cisplatin and S-1 for unresectable advanced squamous cell carcinoma of the esophagus: phase I/II trial results. Oncotarget 2019;10:847-55. [PMID: 30783514 DOI: 10.18632/oncotarget.26614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Zhang B, Qi L, Wang X, Xu J, Liu Y, Mu L, Wang X, Bai L, Huang J. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun (Lond) 2020;40:711-20. [PMID: 33314747 DOI: 10.1002/cac2.12119] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Ueda H, Kawakami H, Nonagase Y, Takegawa N, Okuno T, Takahama T, Takeda M, Chiba Y, Tamura T, Nakagawa K. Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer. Oncologist 2019;24:163-e76. [PMID: 30361422 DOI: 10.1634/theoncologist.2018-0653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Tanaka Y, Yoshida K, Tanahashi T, Okumura N, Matsuhashi N, Yamaguchi K. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. Cancer Sci 2016;107:764-72. [PMID: 27061001 DOI: 10.1111/cas.12943] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
12 Tanaka Y, Yoshida K, Suetsugu T, Imai T, Matsuhashi N, Yamaguchi K. Recent advancements in esophageal cancer treatment in Japan. Ann Gastroenterol Surg 2018;2:253-65. [PMID: 30003188 DOI: 10.1002/ags3.12174] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
13 Hiyoshi Y, Yoshida N, Watanabe M, Kurashige J, Baba Y, Sakamoto Y, Baba H. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. World J Surg 2017;41:480-6. [PMID: 27637603 DOI: 10.1007/s00268-016-3649-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]